American Resistance To Empire

Has JEM Terrorist Leader Masood Azhar Died From Kidney Failure In Pak Army Hospital?

‘Unwell’ Masood Azhar Getting Treatment at Army Hospital in Pakistan: Report

Is Masood Azhar Dead? Speculation Runs Rife On Social Media

Masood Azhar afflicted with renal failure, undergoes regular dialysis at Pakistan Army hospital, say Indian officials

New Delhi: Masood Azhar, the founder of the dreaded terrorist group Jaish-e-Mohammad (JeM), is suspected to be afflicted with renal failure and is under regular dialysis at an army hospital in Rawalpindi in Pakistan, officials said in New Delhi on Saturday.

This suggestion of security officials came after Pakistan Foreign Minister Shah Mahmood Qureshi said the JeM chief is “unwell”.

File photo of JeM chief Masood Azhar. AFP

File photo of JeM chief Masood Azhar. AFP

“Recent reports indicate that Masood Azhar is now afflicted with renal failure and is under treatment and regular dialysis at the army hospital in Rawalpindi, the headquarters of the Pakistan Army,” a senior security official said.

Qureshi said Thursday: “He is in Pakistan, according to my information. He is unwell to the extent that he can’t leave his house, because he’s really unwell”.

The Jaish-e-Mohammad chief was a close associate of Osama bin Laden, terror motivator in several African countries and also known by many as the Pakistani cleric who brought jihad into the religious discourse at mosques in the UK, the official said.

The influence of the 50-year-old terrorist mastermind was so huge that, when he was released by India in exchange for freeing the hijacked Indian Airlines aircraft IC-814 on 31 December, 1999, in Kandahar, Laden hosted a banquet for him the same night. In the banquet, Laden recalled how he and Azhar had first worked together in 1993, the official said.

Azhar was arrested for preaching jihad in Jammu and Kashmir in 1994. One of his British recruits, Omar Shaikh, as a member of the terrorist group Harkat-ul-Ansar (HuA), kidnapped four western tourists in India in 1994 in order to secure the release of Azhar. However, security agencies succeeded in releasing the hostages and arresting Shaikh.

Again in 1995, five western tourists were kidnapped by HuA and eventually killed in order to gain the release of Azhar. Almost immediately after Azhar’s release, Jaish-e-Mohammad was formed and it carried out its first suicide attack in Jammu and Kashmir in April 2000 by striking the Badami Bagh cantonment in Srinagar. The 24-year-old bomber, Asif Sadiq, was one of Azhar’s earliest recruits and student from Birmingham. At this time, Azhar also began using several Al-Qaeda recruits, another official said.

In 1979-1989, after he suffered injuries in the Soviet-Afghan War, he was chosen as the head of Harkat-ul-Ansar’s department of motivation.

In the early 1990s, Azhar became the general secretary of Harkat-ul-Ansar and visited international locations to recruit, raise funds and spread the message of pan-Islamism. Among his destinations were Zambia, Abu Dhabi, Saudi Arabia, Mongolia, the United Kingdom and Albania, the second official said. He also went to Kenya to meet an Al-Qaeda affiliate of Somalia in 1993 and in August 1993, Azhar entered the UK for a speaking, fund-raising, and recruitment tour with the message of jihad.

Azhar made contacts in Britain with people who helped to provide training and logistical support for terrorist plots.

In January 1993, Azhar visited Bangladesh along with Sajjad Afghani, a terrorist leader to facilitate the intrusion of Afghani to India.

Azhar was part of Harkat-ul-Mujahideen or Harkat-ul-Ansar, when he was arrested in 1994 in India for spreading hate. Azhar formed Jaish-e-Mohammad after his release in 1999 when Indian Airlines flight IC 814 was hijacked and taken to Kandahar. Since then, the JeM has been involved in terror attacks in the country. The terror group was responsible for the attack on Indian Parliament on December 13, 2001 in which nine security personnel and officials were killed.

On 2 January, 2016, a heavily armed group of JeM attacked the Pathankot airbase in which seven security personnel were killed. The JeM also carried out the attack on Uri brigade headquarters on 18 September, 2016, killing 17 soldiers and injuring 30 others. On 14 February this year, the JeM carried out a suicide attack on a CRPF bus in Pulwama in Jammu and Kashmir killing at least 40 jawans.

Trump Wants It Both Ways–Protecting Free Speech AND Blocking Criticism of Israel/Jews

[Surely the Jews and Israel are still exempt from public criticism, especially on American campuses (SEE: The End of Free Speech? Criminalizing Criticism of Israel).]

U.S. envoy: No distinction between anti-Zionism and anti-Semitism

Trump said he intends to sign executive order requiring ‘free speech’ at colleges

donald trump cpac
President Donald Trump speaks during CPAC 2019 on March 02, 2019 in National Harbor, Maryland.
 Tasos Katopodis/Getty Images

President Donald Trump said Saturday he would soon sign an executive order requiring American universities and colleges to maintain “free speech” on campuses.

“Today, I am proud to announce that I will be very soon signing an executive order requiring colleges and universities to support free speech if they want federal research funds,” Trump said at the Conservative Political Action Conference.

The announcement came after the president invited Hayden Williams, a conservative activist and student at the University of California Berkeley who was filmed being punched on campus, onstage before announcing the executive order.

“If they want our dollars, and we give it to them by the billions, they’ve got to allow people like Hayden and many other great young people and old people to speak,” Trump said. “Free speech. If they don’t, it will be very costly.”

The White House did not immediately reply to Business Insider’s request for comment.

Trump previously tweeted about Williams’ case, referencing denying federal funds as retribution for schools allowing “violence on innocent people with a different point of view.”

—Donald J. Trump (@realDonaldTrump) February 2, 2017 // ” data-e2e-name=”embed-container” data-media-container=”embed” style=”box-sizing: border-box; margin: 20px 0px;”>

Donald J. Trump


If U.C. Berkeley does not allow free speech and practices violence on innocent people with a different point of view – NO FEDERAL FUNDS?

(Reuters reporting by Katanga Johnson; editing by Diane Craft)

Our Medical Dictatorship–Since when does the government write prescriptions?

[Here in Ohio, the epicenter of the American opioid “witch hunt”, we see the beginnings of a “medical police state”, beginning with the ongoing harassment of pain patients for taking their prescribed pain medicines, Ohio has enacted by state mandate, narcotics testing for many non-opioid drugs, including all benzodiazepines, but even neuropathic pain meds lyrica and neurontin now require the same drug monitoring given to convicted drug offenders and job applicants…but, in addition to all of this, they even do drug monitoring for the probable placebo “drug””ultram”, a.k.a., “tramadol”. Anyone who has been prescribed tramadol for pain knows that it is a cruel joke, intended to replace real medical treatment…as I told my doctor, I would rather take Tylenol than Ultram, at least the tylenol fights pain.--ed.]

Opioid crisis — Since when does the government write prescriptions?



Clearly, something must be done, but federal and state agencies are focusing on the wrong target – legitimate prescribing of opioids – and have insinuated themselves into the doctor-patient relationship as never before. Our governments are taking prescription pads out of the hands of physicians and dictating which, and how much, prescription pain medication may be prescribed for patients. This is chilling and unprecedented.

As of last October, 33 states had instituted laws that restrict opioid prescriptions in some way. Although state laws differ in stringency, they are all intrusive. For example, Florida has a three-day limit on prescribed opioids, with the possibility of a seven-day supply if strict conditions are met. Massachusetts limits first-time patients to a seven-day supply and forbids a second prescription until the first expires.

And nationwide, millions of pain patients, even those who were functioning well with long-term opioid therapy, are being forcibly tapered or having their medicines stopped outright, regardless of their wishes or those of their physicians.


Legal “solutions” to medical issues are dubious, both scientifically and with respect to policy. For example, consider surgical recovery. It is well known that not only does surgical pain vary from patient to patient, but so do patients’ responses to pain medications. Therefore, a standardized, one-size-fits-all dose of a given drug cannot meet the needs of all post-surgery patients, and it will also fail those afflicted with other kinds of pain, both acute and chronic. The principles of pharmacology tell us why.

The effect of a drug on an individual is directly related to his or her weight. All things being equal, no dose of any drug will produce the same effect in a 100-pound person as in a 300-pound one. But weight is only one variable that determines a drug’s effects, and it is not even the most important one.

Americans are now more likely to die of an opioid overdose than in car crash, a new report warns

The rate of metabolism of opioids can vary as much as 30-fold from one individual to the next because of genetic differences in the liver enzymes responsible for the degradation of the drugs. This means that a given dose of an opioid could be dangerously high for one person while too low to be effective for another.

If the science is bad, the legal precedent is worse. In the mad rush to address a complex problem with simplistic thinking, there has been an insidious power shift – toward state governments and federal agencies, in effect, writing prescriptions. This insidious trend has been ignored by the press, civil rights advocates, the public health community and the general public.

In a country so respectful of individuals’ rights, it is unimaginable that we would surrender the sanctity of the patient-physician relationship without a whimper.

This is not likely to end with opioids. Since our government now intrudes into determining the use of pain drugs, why not do so with other potential drugs of abuse? The death rate from sedatives such as Valium and Xanax has soared in recent years, almost always due to combination with other drugs or alcohol. Should government override a physician’s ability to prescribe sedatives to patients because others are abusing them? It would be only a small step to bring those drugs under the same umbrella as opioids.

Indeed, these seeds are already being planted. One of the so-called “addiction specialists” who played a significant role in the current opioid fiasco has now set her sights on benzodiazepine sedatives (which include Klonopin, Valium, Ativan, and Xanax) because of their addiction potential. It is ironic that people who suffer from anxiety will have ample reason to worry even more — about the very real possibility of their medicines being taken away.

And why stop there? The use of drugs such as Ritalin and Adderall for children with ADHD is highly controversial, and both are abused. Many believe that these drugs are overused or shouldn’t be used at all. Should our government instruct pediatricians when and how to use such medicines, or limit the number of pills or the dose they decide is appropriate?

At the core of this disturbing trend is the myth that restriction of certain drugs will eliminate drug abuse. It doesn’t work. It just raises the street price of highly sought-after, abusable drugs.

The decades-long “War on Drugs,” which has never succeeded in controlling abuse or addiction, is now being waged in doctors’ offices, the last place we should want government intrusion. In the name of addressing a crisis, we are sacrificing freedoms in a new, frightening way. That’s a prescription for disaster.


Josh Bloom holds a Ph.D. in organic chemistry and is the director of chemical and pharmaceutical sciences at the American Council on Science and Health.